Skip to Content
MilliporeSigma
All Photos(3)

Documents

G117

Sigma-Aldrich

Glipizide

solid

Synonym(s):

1-Cyclohexyl-3-{4-[2-(5-methylpyrazine-2-carboxamido)ethyl]phenylsulfonyl}urea

Sign Into View Organizational & Contract Pricing
All Photos(3)

About This Item

Empirical Formula (Hill Notation):
C21H27N5O4S
CAS Number:
29094-61-9
Molecular Weight:
445.54
EC Number:
249-427-6
MDL number:
MFCD00072159
UNSPSC Code:
12352200
PubChem Substance ID:
24277839
NACRES:
NA.77

form

solid

Quality Level

100

color

white

solubility

methanol: 1.9 mg/mL
DMSO: 48 mg/mL

SMILES string

Cc1cnc(cn1)C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)NC3CCCCC3

InChI

1S/C21H27N5O4S/c1-15-13-24-19(14-23-15)20(27)22-12-11-16-7-9-18(10-8-16)31(29,30)26-21(28)25-17-5-3-2-4-6-17/h7-10,13-14,17H,2-6,11-12H2,1H3,(H,22,27)(H2,25,26,28)

InChI key

ZJJXGWJIGJFDTL-UHFFFAOYSA-N

Gene Information

human ... ABCC8(6833) , KCNJ1(3758) , KCNJ11(3767)

Looking for similar products? Visit Product Comparison Guide

General description

Potassium inwardly-rectifying channel, subfamily J, member 1 (KCNJ1) codes for a renal outer medullary potassium channel (ROMK1, Kir1.1). Glipizide is an antidiabetic drug, that is used to treat type II diabetes.(5)

Application

Glipizide has been used in:
  • chick embryo yolk sac membrane (YSM) and chorioallantoic membrane (CAM) assay
  • MCF-7 breast cancer assay on chorioallantoic membrane (CAM)
  • metastasis assays
  • rat aortic ring assay
  • in vivo matrigel plug assay
  • 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay
  • flow cytometry
  • western blotting

Biochem/physiol Actions

Potassium inwardly-rectifying channel, subfamily J, member 1 (KCNJ1) plays a vital role in potassium balance. It is an ATP-dependent K+ channel blocker. The encoded protein is liable for the elimination of potassium in exchange for the absorption of sodium by the epithelial sodium channel (ENaC). Mutation in KCNJ1 is linked with several diseases, such as, antenatal Bartter syndrome and diabetes. Glipizide helps to repress the development of tumors and metastasis by preventing angiogenesis.

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 8

1 of 8

Glybenclamide ≥99% (HPLC)

Sigma-Aldrich

G0639

Glybenclamide

USP

USP

1353000

Diluted isosorbide dinitrate (25% mixture with lactose)

Tolbutamide analytical standard

Supelco

T0891

Tolbutamide

Clemastine fumarate salt ≥98% (HPLC)

Sigma-Aldrich

SML0445

Clemastine fumarate salt

Pioglitazone

Sigma-Aldrich

CDS021593

Pioglitazone

Glimepiride Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1617

Glimepiride

Streptokinase from β-hemolytic Streptococcus (Lancefield Group C) lyophilized powder, ≥2,000 units/mg solid

Sigma-Aldrich

S3134

Streptokinase from β-hemolytic Streptococcus (Lancefield Group C)

Daidzin ≥95.0% (HPLC)

Sigma-Aldrich

30408

Daidzin

Glipizide suppresses prostate cancer progression in the TRAMP model by inhibiting angiogenesis
Qi C, et al.
Scientific reports, 6(20), 27819-27819 (2016)
KCNJ1 inhibits tumor proliferation and metastasis and is a prognostic factor in clear cell renal cell carcinoma
Guo Z, et al.
Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine, 36(2), 1251-1259 (2015)
Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment
Karnes JH, et al.
The Pharmacogenomics Journal, 13(5), 430-430 (2013)
K M Pantalone et al.
Diabetes, obesity & metabolism, 14(9), 803-809 (2012-04-11)
It remains uncertain if differences in mortality risk exist among the sulfonylureas, especially in patients with documented coronary artery disease (CAD). The purpose of this study was to assess the overall mortality risk of the individual sulfonylureas versus metformin in
Greg L Plosker
Drugs, 72(17), 2289-2312 (2012-11-23)
Dapagliflozin (Forxiga®) is the first in a novel class of glucose-lowering agents known as sodium-glucose co-transporter-2 (SGLT2) inhibitors and is used in the treatment of patients with type 2 diabetes. By inhibiting the transporter protein SGLT2 in the kidneys, dapagliflozin
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service